If you have been reading about IGF-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-14. Numbers and descriptions here follow the published literature rather than marketing material.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Moisture buildup in buildings may arise from water penetrating areas of the building envelope or fabric, from plumbing leaks, rainwater or groundwater penetration, or from condensation due to improper ventilation, insufficient heating or poor thermal quality of the building envelope. Even something as simple as drying clothes indoors on radiators can increase the risk of mold growth, if the humidity produced is not able to escape the building via ventilation. Mold predominantly affects the airways and lungs. Known effects of mold on health include asthma development and exacerbation, with children and elderly at greater risk of more severe health impacts. Infants in homes with mold have a much greater risk of developing asthma and allergic rhinitis. More than half of adult workers in moldy or humid buildings suffer from nasal or sinus symptoms due to mold exposure. Some varieties of mold contain toxic compounds (mycotoxins). However, exposure to hazardous levels of mycotoxin via inhalation is not possible in most cases, as toxins are produced by the fungal body and are not at significant levels in the released spores.
== Ionization mechanisms == The photoionization mechanism is simplified under vacuum conditions: photon absorption by the analyte molecule, leading to electron ejection, forming a molecular radical cation, M•+. This process is similar to electron ionization common to GC/MS, except that the ionization process is soft, i.e., less fragmentation. In the atmospheric region of an LC/MS system, the ionization mechanism becomes more complex. The unpredictable fate of ions is generally detrimental to LC/MS analysis, but like most processes, once they are better understood, these properties can be exploited to enhance performance. For example, the role of dopant in APPI, first developed and patented for the atmospheric ion source of ion mobility spectrometry (IMS), was adapted to APPI for LC/MS. The basic APPI mechanisms can be summarized by the following scheme: Direct positive ion APPI
== Development == Development of Half-Life 2 began in June 1999, six months after the release of the original Half-Life. It was developed by a team of 82, or around 100 people including voice actors. Valve's president, Gabe Newell, wanted to redefine the FPS genre, saying: "Why spend four years of your life building something that isn't innovative and is basically pointless? If Half-Life 2 isn't viewed as the best PC game of all time, it's going to completely bum out most of the guys on this team." Newell gave his team no deadline and a "virtually unlimited" budget, promising to fund the project himself if necessary. They used Valve's new in-house game engine, Source, developed simultaneously.
Sources: en.wikipedia.org
By September 1900, the British were nominally in control of both Republics, with the exception of north Transvaal. However, they discovered they only controlled the territory their columns physically occupied. Despite the loss of their capitals and half their army, the Boer commanders adopted guerrilla warfare, conducting raids against railways, resource and supply targets, aimed at disrupting the operational capacity of the British Army. They avoided pitched battles and casualties were light. Boer commando units were sent to the district from which its members were recruited, which meant they could rely on local support and knowledge of the terrain and towns, enabling them to live off the land. Their orders were simply to act against the British whenever possible. Their tactics were to strike fast causing as much damage as possible, then withdraw before enemy reinforcements could arrive. The vast distances of the republics allowed Boer commandos freedom to move about and made it nearly impossible for the 250,000 British troops to control the territory effectively using columns alone. As soon as a British column left a town or district, British control of that area faded away. Boer commandos were especially effective during the initial guerrilla phase because Roberts had assumed the war would end with the capture of the capitals and dispersal of the Boer armies. British troops were therefore redeployed out of the area, and had been replaced by lower-quality Imperial Yeomanry and locally-raised irregular corps.
Multi/minicore myopathy is a congenital myopathy usually caused by mutations in either the SELENON and RYR1 genes. It is characterised the presence of multifocal, well-circumscribed areas with reduction of oxidative staining and low myofibrillar ATPase on muscle biopsy. It is also known as Minicore myopathy, Multicore myopathy, Multiminicore myopathy, Minicore myopathy with external ophthalmoplegia, Multicore myopathy with external ophthalmoplegia and Multiminicore disease with external ophthalmoplegia.
Altitude related – Polycythemia can be a normal adaptation to living at high altitudes (see altitude sickness). Many athletes train at high altitude to take advantage of this effect, which can be considered a legal form of blood doping, although the efficacy of this strategy is unclear. Hypoxic disease-associated – for example, in cyanotic heart disease where blood oxygen levels are reduced significantly; in hypoxic lung disease such as COPD; in chronic obstructive sleep apnea; conditions that reduce blood flow to the kidney e.g. renal artery stenosis. Chronic carbon monoxide poisoning (which can be present in heavy smokers) and rarely methemoglobinemia can also impair oxygen delivery. Genetic – Heritable causes of secondary polycythemia include abnormalities in hemoglobin oxygen release, which results in a greater inherent affinity for oxygen than normal adult hemoglobin and reduces oxygen delivery to tissues. Conditions where the secondary polycythemia is not caused by physiologic adaptation, and occurs irrespective of body needs include:
=== Negative or counter selection === In order to increase the specificity of aptamers selected by a given SELEX procedure, a negative selection, or counter selection, step can be added prior to or immediately following target incubation. To eliminate sequences with affinity for target immobilization matrix components from the pool, negative selection can be used where the library is incubated with target immobilization matrix components and unbound sequences are retained. Negative selection can also be used to eliminate sequences that bind target-like molecules or cells by incubating the oligonucleotide library with small molecule target analogs, undesired cell types, or non-target proteins and retaining the unbound sequences.
Sources: en.wikipedia.org
Although for the rest of his career Heseltine's role in Thatcher's downfall earned him enmity from Thatcher's supporters in the Conservative party, this opprobrium was not universal. In a reference to the reluctance of the Cabinet to support Thatcher on the second ballot, Edward Leigh said of Heseltine: "At least he stabbed her in the front". Heseltine believed that he would have defeated Thatcher if she had contested the second ballot. It has been suggested that he should have withdrawn after weakening her on the first ballot, and that he would have been restored to the Cabinet whether or not she continued as prime minister; he writes that this was never seriously suggested at the time.
This is a list of biochemists. It should include those who have been important to the development or practice of biochemistry. Their research or applications have made significant contributions in the area of basic or applied biochemistry.
=== Quad === A quad is a unit of energy equal to 1015 BTUs, or approximately 1.055×1018 J (slightly over one exajoule). It is suitably large to quantify energy usage by nations or by the planet as whole using everyday numbers. For example, in 2004, US energy consumption was about 100 Q/year, while demand worldwide was about 400 Q/year.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.